- Home
- BMRN vs CPB Comparison
BMRN vs CPB Comparison
Compare BMRN & CPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- CPB
- Stock Information
- Founded
- BMRN 1996
- CPB 1869
- Country
- BMRN United States
- CPB United States
- Employees
- BMRN N/A
- CPB N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- CPB Packaged Foods
- Sector
- BMRN Health Care
- CPB Consumer Staples
- Exchange
- BMRN Nasdaq
- CPB Nasdaq
- Market Cap
- BMRN 11.1B
- CPB 9.2B
- IPO Year
- BMRN 1999
- CPB N/A
- Fundamental
- Price
- BMRN $54.09
- CPB $33.23
- Analyst Decision
- BMRN Buy
- CPB Hold
- Analyst Count
- BMRN 24
- CPB 17
- Target Price
- BMRN $91.70
- CPB $35.63
- AVG Volume (30 Days)
- BMRN 1.8M
- CPB 7.4M
- Earning Date
- BMRN 10-28-2025
- CPB 09-03-2025
- Dividend Yield
- BMRN N/A
- CPB 4.69%
- EPS Growth
- BMRN 154.69
- CPB 6.35
- EPS
- BMRN 3.40
- CPB 2.01
- Revenue
- BMRN $3,063,608,000.00
- CPB $10,253,000,000.00
- Revenue This Year
- BMRN $13.32
- CPB N/A
- Revenue Next Year
- BMRN $9.37
- CPB $1.41
- P/E Ratio
- BMRN $15.91
- CPB $16.53
- Revenue Growth
- BMRN 18.36
- CPB 6.40
- 52 Week Low
- BMRN $52.93
- CPB $29.39
- 52 Week High
- BMRN $85.00
- CPB $52.19
- Technical
- Relative Strength Index (RSI)
- BMRN 37.63
- CPB 53.20
- Support Level
- BMRN $55.99
- CPB $32.74
- Resistance Level
- BMRN $59.79
- CPB $34.08
- Average True Range (ATR)
- BMRN 1.57
- CPB 0.85
- MACD
- BMRN -0.40
- CPB 0.10
- Stochastic Oscillator
- BMRN 0.70
- CPB 71.28
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
About CPB Campbell Soup Company
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2024 (July year-end), snacks accounted for nearly half of its revenue, followed by soup (28%), other simple meals (17%), and beverages (7%). Outside its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and recently acquired Rao's (a deal that closed in March 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.